JP7656829B2 - がんの検査方法 - Google Patents

がんの検査方法 Download PDF

Info

Publication number
JP7656829B2
JP7656829B2 JP2021551720A JP2021551720A JP7656829B2 JP 7656829 B2 JP7656829 B2 JP 7656829B2 JP 2021551720 A JP2021551720 A JP 2021551720A JP 2021551720 A JP2021551720 A JP 2021551720A JP 7656829 B2 JP7656829 B2 JP 7656829B2
Authority
JP
Japan
Prior art keywords
molecule
bc2lcn
gal3bp
cancer
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021551720A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021070934A5 (cg-RX-API-DMAC7.html
JPWO2021070934A1 (cg-RX-API-DMAC7.html
Inventor
浩章 舘野
竜也 小田
治 下村
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institute of Advanced Industrial Science and Technology
University of Tsukuba
Original Assignee
National Institute of Advanced Industrial Science and Technology
University of Tsukuba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Institute of Advanced Industrial Science and Technology, University of Tsukuba filed Critical National Institute of Advanced Industrial Science and Technology
Publication of JPWO2021070934A1 publication Critical patent/JPWO2021070934A1/ja
Publication of JPWO2021070934A5 publication Critical patent/JPWO2021070934A5/ja
Application granted granted Critical
Publication of JP7656829B2 publication Critical patent/JP7656829B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
    • G01N33/548—Carbohydrates, e.g. dextran
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4724—Lectins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
    • G01N2333/8121—Serpins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
    • G01N2333/8121—Serpins
    • G01N2333/8125—Alpha-1-antitrypsin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/02—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
JP2021551720A 2019-10-11 2020-10-09 がんの検査方法 Active JP7656829B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019187197 2019-10-11
JP2019187197 2019-10-11
PCT/JP2020/038300 WO2021070934A1 (ja) 2019-10-11 2020-10-09 がんの検査方法

Publications (3)

Publication Number Publication Date
JPWO2021070934A1 JPWO2021070934A1 (cg-RX-API-DMAC7.html) 2021-04-15
JPWO2021070934A5 JPWO2021070934A5 (cg-RX-API-DMAC7.html) 2023-10-13
JP7656829B2 true JP7656829B2 (ja) 2025-04-04

Family

ID=75438180

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021551720A Active JP7656829B2 (ja) 2019-10-11 2020-10-09 がんの検査方法

Country Status (6)

Country Link
US (1) US12618842B2 (cg-RX-API-DMAC7.html)
EP (1) EP4043881A4 (cg-RX-API-DMAC7.html)
JP (1) JP7656829B2 (cg-RX-API-DMAC7.html)
KR (1) KR102896955B1 (cg-RX-API-DMAC7.html)
CN (1) CN114556101B (cg-RX-API-DMAC7.html)
WO (1) WO2021070934A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022182394A (ja) * 2021-05-28 2022-12-08 独立行政法人国立病院機構 抗原固相化デバイス
WO2025187809A1 (ja) * 2024-03-08 2025-09-12 富士フイルム株式会社 検出対象物質を免疫学的に検出する方法、非特異反応を抑制する方法、フコース含有組成物、および試薬キット

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017061449A1 (ja) 2015-10-05 2017-04-13 国立研究開発法人産業技術総合研究所 がん細胞の検出方法、がん細胞内に物質を導入するための試薬、及びがん治療用組成物
WO2018190357A1 (ja) 2017-04-11 2018-10-18 国立研究開発法人産業技術総合研究所 レクチンの固定化方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596476B1 (en) * 1989-12-22 2003-07-22 Abbott Laboratories Hepatitis C assay
JP5977743B2 (ja) 2011-06-15 2016-08-24 三洋化成工業株式会社 磁性シリカ粒子を用いた測定方法及び該測定方法用試薬
WO2013172105A1 (ja) * 2012-05-18 2013-11-21 日東紡績株式会社 膵臓癌を検出するためのマーカー
WO2014126146A1 (ja) 2013-02-14 2014-08-21 独立行政法人産業技術総合研究所 未分化細胞除去方法
JP7386647B2 (ja) 2018-08-13 2023-11-27 東ソー株式会社 糖鎖への親和性が向上したフコース結合性タンパク質、およびその製造方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017061449A1 (ja) 2015-10-05 2017-04-13 国立研究開発法人産業技術総合研究所 がん細胞の検出方法、がん細胞内に物質を導入するための試薬、及びがん治療用組成物
WO2018190357A1 (ja) 2017-04-11 2018-10-18 国立研究開発法人産業技術総合研究所 レクチンの固定化方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KOTHS, K. et al.,Cloning and characterization of a human Mac-2-binding protein, a new member of the superfamily defined by the Macrophage Scavenger Receptor Cysteine-rich Domain,J. Biol. Chem.,1993年,Vol.268, No.19,p.14245-14249,ISSN: 0021-9258
木明琢磨, 外,血清糖タンパク質結合糖鎖を利用した新たな臨床マーカーの開発,臨床病理,2014年,Vol.62補冊,p.140,ISSN: 0047-1860

Also Published As

Publication number Publication date
KR20220079855A (ko) 2022-06-14
EP4043881A1 (en) 2022-08-17
WO2021070934A1 (ja) 2021-04-15
EP4043881A4 (en) 2022-11-23
US12618842B2 (en) 2026-05-05
KR102896955B1 (ko) 2025-12-05
US20220236275A1 (en) 2022-07-28
CN114556101A (zh) 2022-05-27
JPWO2021070934A1 (cg-RX-API-DMAC7.html) 2021-04-15
CN114556101B (zh) 2025-09-26

Similar Documents

Publication Publication Date Title
CN102356316B (zh) 肝内胆管癌的检出、辨别方法
KR101788414B1 (ko) 간암 조기 진단용 바이오마커 및 그 용도
Park et al. Large-scale clinical validation of biomarkers for pancreatic cancer using a mass spectrometry-based proteomics approach
JP7042815B2 (ja) レクチンベースの癌の診断
WO2022063156A1 (zh) 乳腺癌的生物标志物及其应用
EP2805167A1 (en) Biomarkers for gastric cancer and uses thereof
CN104395758A (zh) 用于检测胰腺癌的标志物
US20030138860A1 (en) Cancer detection methods and reagents
WO2022083603A1 (zh) 半胱氨酸蛋白酶抑制剂与Cathepsin复合物作为肿瘤诊断标志物的应用
US12618842B2 (en) Cancer test method
CN115877006B (zh) 卵巢癌相关的生物标志物及其应用
CN120334544B (zh) 鼻咽癌抗体标志物及其应用
KR101144324B1 (ko) 대장암 예후진단용 단백질 마커 디펜신?5와 rod1단백질의 조합 및 이들 각각에 대한 항체를 포함하는 대장암 예후진단키트
JP7709703B2 (ja) 膵臓がんの検出方法及び検出試薬
JP7522412B2 (ja) 前立腺癌の診断を補助する方法
KR20240154464A (ko) 암의 진단용 조성물
KR20240068432A (ko) 혈액 내 단백질 바이오마커를 포함하는 암 진단용 키트
WO2022186318A1 (ja) がん検出方法、がん検査方法、及びこれらに用いるキット
JP2011107064A (ja) クラスリン重鎖に対する自己抗体の免疫測定方法、それに用いるキット、及びそれを用いた癌判定方法
JP2014240772A (ja) Ku70に対する自己抗体の免疫測定方法、それに用いるキットおよびそれを用いた癌判定方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220404

AA64 Notification of invalidation of claim of internal priority (with term)

Free format text: JAPANESE INTERMEDIATE CODE: A241764

Effective date: 20220621

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220819

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231004

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231004

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250212

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250305

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250313

R150 Certificate of patent or registration of utility model

Ref document number: 7656829

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150